First AD

Second AD

Benjamin P. Levy, MD, is clinical director of Medical Oncology at Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital and associate professor of oncology at Johns Hopkins University School of Medicine.

Navigating New Treatment Options in the Frontline Management of Advanced EGFR-Mutant NSCLC

Video content above is prompted by the following:

Briefly comment on the latest OS data from 

andthe recentFDA approval (October 2024) of combination amivantamab and lazertinib as an advancement in the first-line treatment space.

Should this combination become the new standard of care for first-line treatment for certain patients?

What is the remaining role for osimertinib with or without chemotherapy?

How might the recent CRL for subcutaneous amivantamab impact clinical practice over the next year?

Video Series

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Bridging the Gaps in Lung Cancer: 6 Month Update Winter Lung Cancer Conference 2025

Bridging the Gaps: Consensus Viewpoints

Panelists discuss how the MARIPOSA trial (ASCO 2024) showed improved overall survival (OS) with amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant non–small cell lung cancer (NSCLC), supporting its FDA approval (October 2024). This regimen may become standard of care for select patients, but osimertinib with or without chemo remains vital. The complete response letter (CRL) for subcutaneous amivantamab may delay uptake.

Navigating the New Treatment Options in the Frontline Management of Advanced EGFR-Mutant NSCLC